⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
PD-L2 Checkpoint Blockade
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-10 — Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.: Aged-mouse study: PD-L2 is upregulated on senescent cells and shields them from immune clearance; both genetic PD-L2 knockout and anti-PD-L2 antibody therapy reduced senescent-cell burden and restored insulin sensitivity and grip strength in aged mice — establishes PD-L2 as a senescence-immune-evasion checkpoint and an immuno-senolytic-adjacent target. [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.
10-sep-2026
novelty 4
per-area 4
strengthens